Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-β-activated Kinase 1-dependent Signaling.
Sign Up to like & getrecommendations! Published in 2021 at "Hepatology"
DOI: 10.1002/hep.32221
Abstract: BACKGROUND & AIMS Nonalcoholic fatty liver disease (NAFLD) is a key component of metabolic syndrome ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) and is now becoming the leading cause of cirrhosis and… read more here.
Keywords: metabolic stress; breviscapine; signaling breviscapine; nonalcoholic steatohepatitis ... See more keywords